Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.S. & EU Pediatric Drug Regulators Strive For Dialogue, Not Harmonization

Executive Summary

Though differences in timing and design of pediatric oncology trials within U.S. and Europe regulatory frameworks may make harmonization of trial requirements impossible, they should be seen as opportunities to expand understanding of drug development in the field, FDA said at an April 16 meeting of the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee

You may also be interested in...

EU Pharma Denies Skirting Rules On Pediatric Cancer Drug Development

The European pharmaceutical industry has refuted claims that manufacturers are exploiting a loophole in EU legislation to avoid running non-lucrative trials for pediatric oncology drugs.

Europe’s Rx Kindergarten: Pediatric Development Plans Required Before Phase II

Europe's new pediatric regulation requires all new drug development programs to adhere to a Pediatric Investigation Plan approved by the European Medicines Agency

Pediatric Wish List: Longer Exclusivity Reviews, More Public Data

Future legislation should mandate increased public availability of pediatric trial data, Office of Pediatric Therapeutics Director Dianne Murphy said at a June 13 Institute of Medicine drug forum in Washington, D.C

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts